ClinicalTrials.gg
Drug

Selinexor clinical trials

Also written KPT-330, Xpovio and ATG-010.

studies test it
163
open now
49
in phase 3
13
first study started
2012

How each study uses selinexor is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the selinexor studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
3 Jul 2019 · XPOVIO · NDA 212306 (FDA, Drugs@FDA)
European Union
26 Mar 2021 · Nexpovio · EMEA/H/C/005127 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Selinexor
139
CRM1 Nuclear Export Inhibitor KPT-330
22
SINE KPT-330
22
Selective Inhibitor of Nuclear Export KPT-330
21
Nexpovio
5

Brand

Xpovio
29

Development codes

KPT-330
82
ATG-010
18
KCP-330
2

Studies by the year they started

163 studies that test it; most in 2014 (23)

Studies that test selinexor, by start year
YearStudies
20122
20131
201423
201521
20165
20175
20187
20195
202012
202120
202212
202317
202413
202511
20269

By phase

A phase 1/2 study counts in both.

Early Phase 1
1
Phase 1
73
Phase 2
109
Phase 3
13
Phase 4
1
No phase
3

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 40 · Other 123

Karyopharm Therapeutics Inc (31) · National Cancer Institute (NCI) (5) · St. Jude Children's Research Hospital (5) · H. Lee Moffitt Cancer Center and Research Institute (5) · University Health Network, Toronto (4) · Antengene Corporation (4) · Memorial Sloan Kettering Cancer Center (4) · Ruijin Hospital (4)

Often tested with

Tested in the same studies.

Dexamethasone (17) · Venetoclax (7) · Lenalidomide (6) · Pomalidomide (6) · Azacitidine (6) · Bortezomib (5) · Carfilzomib (4) · Daratumumab (4)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 3 phase 3 studies under way

Selinexor is the comparator. A study of two new drugs counts under both.

Reaching primary completion within a year · 19, 2 in phase 3

Studies that test selinexor, phase 3 first.

Studies

Open first, then newest update. How each study uses selinexor is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 163

See all 163 studies that test selinexor →

Given beside what is tested · 11 — selinexor is usual care or a partner of the new treatment
As the comparator · 4 — what is tested is compared with selinexor

What changed recently

From the registry's own updates since Oct 18, 2026.

Codes

What other systems call selinexor · ClinicalTrials.gg INT006398

  • MeSH (NLM) C585161selinexorConfirmed ClinicalTrials.gov, NLM, Wikidata
  • UNII (FDA) 31TZ62FO8FSELINEXORConfirmed FDA, NLM, Wikidata
  • RxNorm 2178390One source FDA
  • Wikidata Q27256082selinexorConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C102546SelinexorOne source FDA
  • DrugBank DB11942One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.